Androgen News and Research

RSS

Study uncovers new regulator of prostate cancer metastasis

A transcription factor normally associated with androgen receptor activity in prostate cancer has a newly discovered role in controlling lipid biosynthesis, according to a Northwestern Medicine study published in Nature Genetics.

10 May 2022

Understanding sex differences in the pathophysiology of SARS-CoV-2 infection

A recent study published in the journal Immunology analyzed whether sex mattered in the immune response to SARS-CoV-2.

29 Apr 2022

Findings of the HITCH randomized clinical trial show lack of improvement in COVID-19 on temporary androgen suppression

Researchers investigated whether temporary androgen suppression by degarelix improved the clinical outcomes among male patients hospitalized with COVID-19.

27 Apr 2022

CryoEM reveals never-before-seen details of the human androgen receptor

Scientists at Memorial Sloan Kettering Cancer Center (MSK) have glimpsed never-before-seen details of the human androgen receptor -; the protein inside of cells that responds to male-typical hormones like testosterone.

20 Apr 2022

Breakthrough finding reveals how male sex hormones contribute to cancer-related sex bias

Patients with cancers stemming from non-reproductive organs, such as bladder and liver cancer, have striking discrepancies in incidence, progression, response to treatment and survival outcomes depending on their sex. In almost all cases, male patients have worse prognoses and outcomes.

15 Apr 2022

Researchers find novel inhibitors that may suppress oncogenesis of metastatic prostate cancer

Researchers have found that treating prostate cancer cells with novel cyclin-dependent kinase 19 (CDK19) and homologous cyclin-dependent kinase 8 (CDK8) inhibitors reduces their potential to migrate into and invade surrounding structures.

13 Apr 2022

High-throughput screening assay could identify new prostate cancer drugs

A novel high-throughput screening assay is designed to identify inhibitors of the androgen receptor, which plays a critical role in the progression of prostate cancer.

6 Apr 2022

Do androgens play a role in COVID-19 severity?

Researchers assess the association between the AR polyQ polymorphism with COVID-19 severity using a large cohort of 1,136 COVID-19 male patients.

5 Apr 2022

Study reveals the oncometabolite role of progesterone in advanced prostate cancer

In a study published in Cell Reports Medicine, a group of Chinese scientists revealed the oncometabolite role of progesterone in advanced prostate cancer and strategies to eliminate its oncogenic effect as an aspect of prostate cancer treatment.

15 Mar 2022

Novel radioligand therapy shown to increase survival of metastatic prostate cancer patients

A novel prostate cancer treatment-;225Ac-PSMA-617 radioligand therapy-;has been shown to increase the progression free survival (PFS) and overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC) patients, according to research published by The Journal of Nuclear Medicine.

9 Mar 2022

Study uncovers new clues about the cellular processes that can lead to androgen deficiency

A laboratory study at the Miller School of Medicine's Desai Sethi Urology Institute has uncovered new clues about the cellular processes that can lead to deficiencies of androgens (male hormones) such as testosterone.

4 Mar 2022

Choice of initial treatment not related to depression, emotional well-being in prostate cancer patients

Depression and other mental health outcomes are similar for men choosing different options for initial treatment of localized prostate cancer, reports a study in The Journal of Urology, an Official Journal of the American Urological Association.

3 Mar 2022

Study finds the optimal duration of treatments for patients with high-risk prostate cancer

Patients receiving radiotherapy to treat high-risk prostate cancer also benefit from androgen deprivation therapy.

25 Feb 2022

New combination treatment strategy for managing metastatic hormone-sensitive prostate cancer

A new drug, administered in combination with standard androgen-deprivation therapy and docetaxel chemotherapy, increased survival in patients with metastatic hormone-sensitive prostate cancer, according to a trial published in The New England Journal of Medicine.

23 Feb 2022

Combination of three drugs extends the survival of patients with metastatic, hormone-sensitive prostate cancer

Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer, a disease that is fatal in most cases.

18 Feb 2022

Nutritional supplements used to improve athletic performance can pose risks to the heart

Nutritional supplements taken to boost athletic performance can pose risks to the heart, according to a European Society of Cardiology (ESC) statement published today in the European Journal of Preventive Cardiology, a journal of the ESC.

27 Jan 2022

Study findings could help guide treatment planning for men with high-risk prostate cancer

Results of a large study led by UCLA Jonsson Comprehensive Cancer Center researchers could help guide treatment planning for patients with high-risk prostate cancer.

20 Jan 2022

Addition of hormone therapy to radiotherapy treatments improves survival in prostate cancer patients

Prostate cancer is the leading cause of cancer in men worldwide, and radiotherapy is one of the common forms of treatment.

18 Jan 2022

Black men with prostate cancer may have improved response to radiation therapy than white men

UCLA Jonsson Comprehensive Cancer Center researchers leading a meta-analysis of seven randomized trials found an "unexpected result": Although Black men appeared to have more aggressive disease when they enrolled in clinical trials of radiation therapy for prostate cancer, their treatment outcomes and disease-specific outcomes were better than those of their white counterparts.

30 Dec 2021

Study provides new insights into molecular drivers of treatment resistance in prostate cancer

An international research team co-led by scientists at Roswell Park Comprehensive Cancer Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has identified an important accelerator of treatment-resistant prostate cancer.

14 Dec 2021